Skip to content
2000
Volume 13, Issue 8
  • ISSN: 1574-888X
  • E-ISSN: 2212-3946

Abstract

Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.

Loading

Article metrics loading...

/content/journals/cscr/10.2174/1574888X13666180731155038
2018-11-01
2025-05-03
Loading full text...

Full text loading...

/content/journals/cscr/10.2174/1574888X13666180731155038
Loading

  • Article Type:
    Review Article
Keyword(s): gene therapy; iHSC; iPSC; Leukemia; malignancy modeling; miRNAs; reprogrammed NK cells; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test